Last $13.72 USD
Change Today +0.13 / 0.96%
Volume 2.4M
NKTR On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 5:20 PM 09/17/14 All times are local (Market data is delayed by at least 15 minutes).

nektar therapeutics (NKTR) Snapshot

Open
$13.59
Previous Close
$13.59
Day High
$13.93
Day Low
$13.53
52 Week High
03/4/14 - $15.34
52 Week Low
11/7/13 - $8.87
Market Cap
1.7B
Average Volume 10 Days
1.3M
EPS TTM
$-1.18
Shares Outstanding
127.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NEKTAR THERAPEUTICS (NKTR)

nektar therapeutics (NKTR) Related Businessweek News

No Related Businessweek News Found

nektar therapeutics (NKTR) Details

Nektar Therapeutics, a clinical-stage biopharmaceutical company, develops drug candidates that utilize its PEGylation and polymer conjugate technology platforms in the United States. Its product pipeline comprises drug candidates in therapeutic areas, including oncology, pain, anti-infectives, and immunology. The company’s drug candidates in clinical development stage comprise naloxegol, an opioid antagonist, which has completed Phase III clinical trial for treating opioid-induced constipation; BAY41-6551 that is in Phase III clinical trial to treat gram-negative pneumonias; NKTR-181, which has completed Phase II clinical trial for chronic pain; and NKTR-171 that is in Phase I clinical trial to treat neuropathic pain. Its other product candidates comprise etirinotecan pegol, a topoisomerase I inhibitor, which is in Phase III clinical trial for metastatic breast cancer and in Phase II clinical trial for second-line metastatic colorectal cancer; and in combination with 5-fluorouracil/leucovorin to treat metastatic colorectal cancer that has completed Phase I clinical trial. In addition, the company offers preclinical drug candidates comprising opioid/NKTR-118 to treat chronic pain; NKTR-192 to treat acute pain; and NKTR-214, a cytokine immunostimulatory therapy to treat oncology. Nektar Therapeutics has collaboration with Bayer Healthcare LLC to develop BAY41-6551, which is an inhaled solution of amikacin, an aminoglycoside antibiotic; and a license agreement with AstraZeneca AB to develop and commercialize naloxegol and naloxegol fixed-dose combination program. Further, it has license, manufacturing, and supply agreements with Amgen Inc.; MAP Pharmaceuticals, Inc.; Merck & Co., Inc.; Ophthotech Corporation; Pfizer, Inc.; F. Hoffmann-La Roche Ltd (Roche), Regado Biosciences, Inc.; and UCB Pharma. The company was founded in 1990 and is headquartered in San Francisco, California.

445 Employees
Last Reported Date: 02/27/14
Founded in 1990

nektar therapeutics (NKTR) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $831.2K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $524.3K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $504.2K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $459.7K
Compensation as of Fiscal Year 2013.

nektar therapeutics (NKTR) Key Developments

Nektar and AstraZeneca Win FDA Approval of Constipation Drug, Looks to the Future

Seven years after moving a new kind of drug into its first clinical trials in humans, Nektar Therapeutics Inc. and AstraZeneca have their first drug approval. Movantik, a drug aimed at relieving constipation in people who take powerful pain-killing opioid drugs, won approval September 16, 2014 from the Food and Drug Administration. Approval, which was largely expected by analysts, means San Francisco-based Nektar will receive $35 million from AstraZeneca. What's more, a $70 million payment from AstraZeneca last year will convert from essentially a loan, and Nektar will get $100 million when AstraZeneca starts selling Movantik in the United States and another $40 million when European sales begin. Nektar would have had to repay the $70 million if the FDA did not require a cardiovascular safety study before approval.

Nektar Therapeutics Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Revenue Guidance for 2014

Nektar Therapeutics announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company announced total revenue of $28,513,000 compared to $33,862,000 for the same period a year ago. Loss from operations was $22,916,000 compared to $32,605,000 for the same period a year ago. Loss before provision for income taxes was $32,442,000 compared to $42,543,000 for the same period a year ago. Net loss was $32,637,000 compared to $42,748,000 for the same period a year ago. Basic and diluted net loss per share was $0.26 compared to $0.37 for the same period a year ago. The decrease in revenue is primarily due to decreased manufacturing activity. For the six months, the company announced total revenue of $48,284,000 compared to $56,866,000 for the same period a year ago. Loss from operations was $59,318,000 compared to $77,711,000 for the same period a year ago. Loss before provision for income taxes was $78,452,000 compared to $97,394,000 for the same period a year ago. Net loss was $78,838,000 compared to $97,811,000 for the same period a year ago. Basic and diluted net loss per share was $0.63 compared to $0.85 for the same period a year ago. Net cash used in operating activities was $71,375,000 compared to $72,448,000 for the same period a year ago. Purchases of property and equipment were $5,192,000 compared to $794,000 for the same period a year ago. Revenue for the full year 2014 is still expected to be between $190 million and $195 million, including $20 million of noncash royalty revenue from UCB's Cimzia, and Roche’s Mircera. This guidance includes the anticipation of recognition of 2 significant milestones in the third quarter of 2014, pursuing to the agreement with AstraZeneca signed last August.

Nektar Therapeutics Presents at Jefferies 2014 Boston Healthcare Summit, Aug-06-2014

Nektar Therapeutics Presents at Jefferies 2014 Boston Healthcare Summit, Aug-06-2014 . Venue: Boston Harbor Hotel, Boston, Massachusetts, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NKTR:US $13.72 USD +0.13

NKTR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Depomed Inc $15.03 USD +0.12
Impax Laboratories Inc $24.76 USD +0.76
Ironwood Pharmaceuticals Inc $12.52 USD +0.28
Sucampo Pharmaceuticals Inc $6.60 USD -0.03
Theravance Inc $18.41 USD -0.04
View Industry Companies
 

Industry Analysis

NKTR

Industry Average

Valuation NKTR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12.2x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEKTAR THERAPEUTICS, please visit www.nektar.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.